Glycogen synthase kinase‐3 inhibitors suppress the AR‐V7‐mediated transcription and selectively inhibit cell growth in AR‐V7‐positive prostate cancer cells
Daisuke Nakata(Takeda (Japan)), Takahito Hara(Takeda (Japan)), Ryokichi Koyama(Takeda (Japan)), Tatsuya Watanabe(Takeda (Japan)), Satoshi Kitazawa(Takeda (Japan)), Kazuhide Nakayama(Takeda (Japan))
Cited by 5
Related Papers
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
|PubMed|2003|427
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response
|Proceedings of the National Academy of Sciences|2018|172
TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma
|Oncotarget|2018|144
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
|Bioorganic & Medicinal Chemistry|2011|126
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
|The Journal of Steroid Biochemistry and Molecular Biology|2012|116